Toxicity classification and evaluation of four pharmaceuticals classes: Antibiotics, antineoplastics, cardiovascular, and sex hormones

Toxicology

Volumn 203, Issue 1-3, 2004, Pages 27-40

  Sanderson, Hans ^a   Brain, Richard A ^a   Johnson, David J ^a   Wilson, Christian J ^a   Solomon, Keith R ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Antibiotics; Antineoplastics; Cardiovascular; ECOSAR; Environmental risks; Sex hormones

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; SEX HORMONE;

AQUATIC ENVIRONMENT; ARTICLE; DRUG INFORMATION; ENVIRONMENTAL EXPOSURE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; TOXICITY TESTING;

ALGAE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CALIBRATION; CARDIOVASCULAR AGENTS; DAPHNIA; FISHES; GONADAL STEROID HORMONES; STRUCTURE-ACTIVITY RELATIONSHIP;

ALGAE;

EID: 4444268080     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2004.05.015     Document Type: Article

References (66)

1. Andersen H., Siegrist H., Halling-Sørensen B., Ternes T.A. Fate of estrogens in a municipal sewage treatment plant. Environ. Sci Technol. 37:2003;4021-4026
2. Auwerx J. Review: PPARγ, the ultimate thrifty gene. Diabetologia. 42:1999;1033-1049
3. Blin N., Federici C., Koschielniak T., Strosberg D. Predictive quantitative structure-activity relationships (QSAR) analysis of β3-adrenergic ligands. Drug Design Disc. 12:1995;297-311
4. Bradbury S.P., Russom C.L., Ankley G.T., Schultz T.W., Walker J.D. Overview of data and conceptual approaches for deivation of quantitative structure-activity relationships for ecotoxicological effects of organic chemicals. Environ. Toxicol. Chem. 22:2003;1789-1798
5. Brain R.A., Johnson D.J., Sanderson H., Mabury S.A., Lam M., Solomon K.R. Effects of 25 pharmaceutical compounds to Lemna gibba using 7-day static renewal test. Environ. Toxicol. Chem. 23:2004;371-382
6. Canadian Bacterial Surveillance Network, 2004: http://microbiology. mtsinai.on.ca/research/cbsn.shtml, (accessed 02-02-04).
7. Christensen F. Pharmaceuticals in the environment - a human risk? Regul. Toxicol. Pharm. 28:1998;212-221
8. Cleuvers, M., 2003. Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid. Ecotoxicol. Environ. Saf., Online: http://dx.doi.org/10.1016/S0147-6513(03)00141-6.
9. Cronin M.T.D., Aptula A.O., Dearden J.C., Duffy J.C., Netzeva T.I., Patel H., Rowe P.H., Schultz T.W., Worth A.P., Voutzoulidis K., Schüürmann G. Structure-based classification of antibacterial activity. J. Chem. Inf. Comput. Sci. 42:2002;869-878
10. Daughton C.G., Ternes T.A. Special report. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ. Health Perspect. 107:1999;907-938
11. Debernard S., Rossignol F., Couillaud F. The HMG-CoA reductase inhibitor fluvastatin inhibits insect juvenile hormone biosynthesis. Gen. Comp. Endocrinol. 95:1994;92-98
12. deFur, P.L., Crane, M., Ingersoll, C.G., Tattersfield, L.J., 1999. Endocrine disruption in invertebrates. In: Endocrinology, Testing, and Assessment. SETAC Press, 303 pp.
13. DK-EPA, 2002. Feminization of fish. The effect of estrogenic compounds and their fate in sewage treatment plants and nature. http://www.mst.dk/udgiv/ publications/2002/87-7972-305-5/pdf/87-7972-306-3.pdf (accessed 02-02-04).
14. BCR-abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Research 60, 3127-3131.
15. Dzialowski, E.M., Brooks, B.W., Turner, P.K., Huggett, D.B., 2003. Influence of β-adrenergic blockers on Daphnia magna heart rate, respiration, and reproduction. In: Proceedings of the SETAC North America 23rd Annual Meeting. Austin, TX, USA (Poster).
16. EMEA, 2003. The European Agency for the Evaluation of Medicinal Products Pre-Authorization Evaluation of Medicines for Human Use. Committee for proprietary medicinal products, draft note for guidance on environmental risk assessment of medicinal products for human use. CPMP/SWP/4447/00 draft. http://www.emea.eu.int (accessed 02-02-04).
17. Escher B.I., Hermens J.L.M. Modes of action in ecotoxicology: their role in body burdens, species sensitivity, QSARs, and mixture effects. Environ. Sci. Technol. 36:2002;4201-4216
18. Escriva H., Safi R., Hanni C., Langlois M.C., Saumitou-Laprade P., Stehelin D., Capron A., Pierce R., Laudet V. Ligand binding was acquired during evolution of nuclear receptors. Proc. Natl. Acad. Sci. U.S.A. 94:1997;6803-6808
19. EU, 2001a. CSTEE. Discussion paper on environmental risk assessment of medical products for human use (non-genetically modified organisms (non-GMO) containing). CPMPpaperRAssessHumPharm12062001/D(01). Brussels, Belgium
20. EU, 2001b. White paper. Strategy for a future chemicals policy, COM (2001) 88 Final. http://europa.eu.int/comm/environment/chemicals/0188_en.pdf (accessed 02-02-04).
21. EU, 2001c. Communication from the commission on a community strategy against antimicrobial resistance. http://europa.eu.int/comm/health/ph/others/ antimicrob_resist/am_02_en.pdf (accessed 02-02-04).
22. Halling-Sørensen B., Nors-Nielsen S., Lansky P.F., Ingerslev F., Holten-Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere. 36:1998;357-393
23. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic envionment: a review of recent research data. Toxicol. Lett. 131:2002;5-17
24. Hellenbrecht D., Enekel J. Estimation of the non-specific cardiovascular toxicity of beta-adrenoceptor blocking drugs with different hydrophobic properties in the cat. Artzmittel Forschung. 34:1984;980-983
25. Hermens J. QSAR in environmental sciences and drug design. Sci. Total Environ. 109-110:1991;1-7
26. Hirsch R., Ternes T., Haberer K., Kratz K.L. Occurrence of antibiotics in the aquatic environment. Sci Total Environ. 225:1999;109-118
27. Huggett D.B., Brooks B.W., Peterson B., Foran C.M., Schlenk D. Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (β-blockers) on aquatic organisms. Arch. Environ. Contam. Toxicol. 43:2002;229-235
28. Huggett D.B., Cook J.C., Ericson J.F., Williams R.T. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Hum. Ecol. Risk Assess. 9:2003;1789-1799
29. Jones O.A.H., Voulvoulis N., Lester J.N. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 36:2002;5013-5022
30. Jørgensen S.E., Halling-Sørensen B. Editorial: drugs in the environment. Chemosphere. 40:2000;691-699
31. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proc. Natl. Acad. Sci. U.S.A. 94:1997;4318-4323
32. Klopman G., Saiakhov R., Rosenkrantz H.S. Multiple computer-automated structure evaluation study of aquatic toxicity II. Fathead minnow. Environ. Toxicol. Chem. 19(2):2000;441-447
33. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.R., Buxton H.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams 1999-2000: a national reconnaissance. Environ. Sci. Technol. 36:2002;1202-1211
34. Kümmerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitas in relation to other sources - a review. Chemosphere. 45:2001;957-969
35. Kümmerer K., Steger-Hartmann T., Baranyai A., Bürhaus I. Prüfung des biologischen abbaus der zytostatika Cyclophosphamid und Ifosfamid mit dem closed bottle test (OECD 301D). Zbl Hyg. 198:1996;215-225
36. Kümmerer K., Al-Ahmad A., Bertram B., Wießler M. Biodegradability of antineoplastics compounds in screening tests: influence of glucosidation and stereochemistry. Chemosphere. 40:2000;767-773
37. Levy S.B. The challenge of antibiotic resistance. Sci. Am. March:1998;46-53
38. Martindale, 2002. In: Sweetman, S.C. (Ed.), Martindale, the Complete Drug Reference, 33rd ed. Pharmaceutical Press Chicago, USA, 2483 pp.
39. Metcalfe C.D., Miao X.S., Koenig B.G., Struger J. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower great lakes. Can. Environ. Toxicol. Chem. 22:2003;2881-2889
40. Montforts, M., Blackwell, P., Boxall, A., Halling-Sørensen, B., Hermansen, S., Ingerslev, F., Jacobsen, AM., Kay, P., ter Laak, T., Moltmann, J., Schmitt, H., Søeborg, T., Tarazona, J., Tolls, J., Verschoor, A., 2003. ERAVMIS: environmental risk assessment of veterinary medicines in slurry: http://www.silsoe.cranfield.ac.uk/ecochemistry/eravmis/eravguid1.pdf (accessed 02-02-04).
41. Montsford M.H.M.M., Kalf D.F., van Vlaardingen P.L.A., Linders J.B.J.H. The exposure assessment of veterinary medicinal products. Sci. Total Environ. 225:1999;119-133
42. Moore D.R.J., Breton R.L., MacDonald D.B. A comparison of model performance for six quantitative structure-activity relationship packages that predict acute toxicity to fish. Environ. Toxicol. Chem. 22:2003;1799-1809
43. Nabholz, V.J., Clements, R.G., Zeeman, M.G., Osborn, K.C., Wedge, R., 1993. Validation of structure activity relationships used by the USEPA's office of pollution prevention and toxics for the environmental hazard assessment of industrial chemicals. In: Gorsuch, J.W., Dwyer, F.J., Ingersoll, C.G., LaPoint, T.W. (Eds.), ASTM, 1216. 1993. Environmental Toxicology and Risk Assessment, second volume. ASTM STP 1216, American Society for Testing and Materials, PA, USA, pp. 571-591.
44. Nawaz M.S., Erickson B.D., Khan A.A., Khan S.A., Pothuluri J.V., Rafii F., Sutherland J.B., Wagner R.D., Cerniglia C.E. Human health impact and regulatory issues involving antimicrobial resistance in the food animal production environment. Regul. Res. Perspect. 1:2001;10-16
45. Niederlehner R.B., Cairns J. Jr., Smith E.P. Modeling acute and chronic toxicity of nonpolar narcotic chemicals and mixtures to Ceriodaphnia dubia. Ecotox. Environ. Saf. 39:1998;136-146
46. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., Lenhard J.M., Hull-Ryde E.A., Mohr C.P., Blanchard S.G., Parks D.J., Moore L.B., Lehman J.M., Plunket K., Miller A.B., Milburn M.V., Kliewer S.A., Willson T.M. A peroxisome proliferator activated receptor γ ligand inhibys adipocyte differntiation. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6102-6106
47. OECD, 2001. Guidance document on the use of the harmonized system for the classification of chemicals, which are hazardous for the aquatic environment, OECD series on testing and assessment, number 27. ENV/JM/MONO, p. 8.
48. POSEIDON, 2004: http://www.eu-poseidon.com/ (accessed 02-02-04).
49. Ren S. Ecotoxicity prediction using mechanism- and non-mechanism-based QSARs: a preliminary study. Chemosphere. 53:2003;1043-1065
50. Salvito D.T., Senna R.J., Federle T.W. A framework for prioritizing fragrance materials for aquatic risk assessment. Environ. Toxicol. Chem. 21:2002;1301-1308
51. Sanderson H., Johnson D., Wilson C., Brain R., Solomon K.R. Probabilistic hazard assessment of environmentally occurring pharmaceuticals acute toxicity to fish. Toxicol. Lett. 144:2003;383-395
52. Sanderson H., Johnson D., Reitsma T., Wilson C., Brain R., Solomon K.R. Ranking amd prioritization of environmental risks of pharmaceuticals in surface waters. Regul. Toxicol. Pharm. 39:2004a;158-183
53. Sanderson, H., Dyer, S., Nabholz, V.J., 2004b. QSAR's extrapolation. In: Solomon, K.R., Sibley, P.L., Sanderson, H., Richards, S.M., Dyer, S., Brock, T.C.M., van den Brink P., Posthuma, L., de Zwart, D. (Eds.), Extrapolation Practice for Ecological Effect Characterization of Chemicals (EXPECT). SETAC Press, in press.
54. Schmieder P.K., Ankley G., Mekenyan O., Walker J.D., Bradbury S. Quantitative structure-activity relation models for prediction of estrogen receptor binding affinity of structurally diverse chemicals. Environ. Toxicol. Chem. 22:2003;1844-1854
55. Seiler J.P. Pharmacodynamic activity of drugs and ecotoxicology - can the two be connected? Toxicol. Lett. 131:2002;105-115
56. Steger-Hartmann T., Kümmerer K., Schecker J. Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by two-step solid-phase extraction and gas chromatography-mass spectrometry. J. Chromatogr. A. 726:1996;179-184
57. Stuer-Lauridsen, F., Hansen, L., Birkved, M., Kjølholt, J., Mikkelsen, S., 2002. Litteraturudredning vedrørende human medicin i miljøet. Miljøprojekt Nr. 661. Danish EPA.
58. Svenson A., Allard A.S., Ek M. Removal of estrogenicity in Swedish municipal sewage treatment plants. Water Res. 37:2003;4433-4443
59. Tattersfield, L., Matthiessen, P., Campbell, P., Grandy, N., Lange R., 1997. Endocrine Modulators and Wildlife: Assessment and Testing. SETAC Press, 126 pp.
60. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res. 11:1998;3245-3260
61. Tong W., Perkins R., Fang H., Hong H., Xie Q., Branham W., Sheehan D.M., Anson J.F. Development of quantitative structure-activity relations (QSARs) and their use for priority setting in the testing strategy of endocrine disruptors. Regul. Res. Perspect. 1:2002;1-16
62. Vamecq J., Latruff N. Review: medical significance of peroxisome proliferator activated receptors. Lancet. 354:1999;141-148
63. Vosper H., Khoudoli G.A., Graham T.L., Palmer C.A.N. Peroxisome proliferator-activated agonists, hyperlidaemia, and atherosclerosis. Pharm. Ther. 95:2002;47-62
64. Weigel L.M., Clewell D.B., Gill S.R., Clark N.C., McDougal L.K., Flannagan S.E., Kolonay J.F., Shetty J., Killgore G.E., Tenover F.C. Genetic analysis of a high-level Vancomycin-resistant isolate of Staphylococcus aureus. Science. 302:2003;1569-1571
65. WHO, 2001 WHO, 2001: http://www.who.int/csr/resources/publications/ drugresist/WHO_CDS_CSR_DRS_2001_2_EN/en/ (accessed 02-02-04).
66. Zeeman M., Auer C.M., Clements R.G., Nabholz J.V., Boethling R.S. US EPA regulatory perspectives on the use of QSAR for new and existing chemical evaluations. SAR QSAR Environ. Res. 3:1995;179-201